Vaxart (NASDAQ: VXRT) recently reported preliminary results from phase 1 study of its tablet COVID-19 vaccine candidate. Although there were some positive data in those results, many investors worried about the failure of the experimental vaccine to produce neutralizing antibodies in study participants. The biotech stock plunged after the clinical update. In this Motley Fool Live video recorded on Feb. 3, 2021 , Fool.com contributors Keith Speights and Brian Orelli answer a viewer's question about whether Vaxart still has a future.
For further details see:
Does Vaxart Still Have a Future?